TargetPeroxisome proliferator-activated receptor gamma/Nuclear receptor corepressor 1/Retinoic acid receptor RXR-alpha(Human)
Flare Therapeutics
US Patent
Flare Therapeutics
US Patent
Affinity DataEC50: 55nMAssay Description:Compound potency (EC50) and maximal extent of NCOR1 recruitment to PPARG were assessed a TR-FRET binding assay measuring association of a biotinylate...More data for this Ligand-Target Pair
TargetPeroxisome proliferator-activated receptor gamma/Nuclear receptor corepressor 1/Retinoic acid receptor RXR-alpha(Human)
Flare Therapeutics
US Patent
Flare Therapeutics
US Patent
Affinity DataEC50: 550nMAssay Description:Compound potency (EC50) and maximal extent of NCOR1 recruitment to PPARG were assessed a TR-FRET binding assay measuring association of a biotinylate...More data for this Ligand-Target Pair
TargetPeroxisome proliferator-activated receptor gamma/Nuclear receptor corepressor 1/Retinoic acid receptor RXR-alpha(Human)
Flare Therapeutics
US Patent
Flare Therapeutics
US Patent
Affinity DataEC50: 550nMAssay Description:Compound potency (EC50) and maximal extent of NCOR1 recruitment to PPARG were assessed a TR-FRET binding assay measuring association of a biotinylate...More data for this Ligand-Target Pair
TargetPeroxisome proliferator-activated receptor gamma/Nuclear receptor corepressor 1/Retinoic acid receptor RXR-alpha(Human)
Flare Therapeutics
US Patent
Flare Therapeutics
US Patent
Affinity DataEC50: 550nMAssay Description:Compound potency (EC50) and maximal extent of NCOR1 recruitment to PPARG were assessed a TR-FRET binding assay measuring association of a biotinylate...More data for this Ligand-Target Pair
TargetPeroxisome proliferator-activated receptor gamma/Nuclear receptor corepressor 1/Retinoic acid receptor RXR-alpha(Human)
Flare Therapeutics
US Patent
Flare Therapeutics
US Patent
Affinity DataEC50: 550nMAssay Description:Compound potency (EC50) and maximal extent of NCOR1 recruitment to PPARG were assessed a TR-FRET binding assay measuring association of a biotinylate...More data for this Ligand-Target Pair
TargetPeroxisome proliferator-activated receptor gamma/Nuclear receptor corepressor 1/Retinoic acid receptor RXR-alpha(Human)
Flare Therapeutics
US Patent
Flare Therapeutics
US Patent
Affinity DataEC50: 550nMAssay Description:Compound potency (EC50) and maximal extent of NCOR1 recruitment to PPARG were assessed a TR-FRET binding assay measuring association of a biotinylate...More data for this Ligand-Target Pair
TargetPeroxisome proliferator-activated receptor gamma/Nuclear receptor corepressor 1/Retinoic acid receptor RXR-alpha(Human)
Flare Therapeutics
US Patent
Flare Therapeutics
US Patent
Affinity DataEC50: 5.50E+3nMAssay Description:Compound potency (EC50) and maximal extent of NCOR1 recruitment to PPARG were assessed a TR-FRET binding assay measuring association of a biotinylate...More data for this Ligand-Target Pair






